July 7, 2020

Glytec and ThunderCat Technology Partner to Improve Glycemic Management at VA Hospitals

Glytec and ThunderCat Technology Partner to Improve Glycemic Management at VA Hospitals Collaboration Seeks to Improve Outcomes and Reduce Cost of Care for the 25% of Veterans with Diabetes WALTHAM, MASS. (July 7, 2020) – Glytec, the only provider of insulin management software across the continuum of care, and ThunderCat Technology, a Service-Disabled Veteran-Owned Small Business (SDVOSB) that delivers technology …

June 15, 2020

Glytec’s Glucommander Software Combined with Continuous Glucose Monitoring Enables Patients with Diabetes to Improve Time in Range by More than 25% in Only Four Weeks

Glytec’s Glucommander Software Combined with Continuous Glucose Monitoring Enables Patients with Diabetes to Improve Time in Range by More than 25% in Only Four Weeks First study to utilize CGM data with FDA-cleared, cloud-based titration software suggests significantly improved outcomes for patients while optimizing clinical resources WALTHAM, MASS. (June 16, 2020) – Glytec, the only provider of insulin management software across …

June 11, 2020

Healthcare Providers Showcase Value of Glytec’s Insulin Management Software During Diabetes Technology Society’s Virtual Hospital Poster Session

Healthcare Providers Showcase Value of Glytec’s Insulin Management Software During Diabetes Technology Society’s Virtual Hospital Poster Session Event Includes Six Studies on Quality and Cost Improvements Achieved Through Glytec eGMS® WALTHAM, MASS. (June 11, 2020) – Glytec, the only provider of insulin management software across the continuum of care, announced today that healthcare providers from five separate health systems will present studies …

April 27, 2020

Uncontrolled hyperglycemia might be COVID-19 mortality risk factor

APRIL 27, 2020 Eleanor McDermid Uncontrolled hyperglycemia might be COVID-19 mortality risk factor medwireNews: A descriptive analysis of US patients with COVID-19 reports a high in-hospital mortality rate in those with uncontrolled hyperglycemia. The rate was markedly higher than that seen in patients with confirmed diabetes, although Valerie Garrett (Glytec Inc., Waltham, Massachusetts, USA) and co-researchers note that they did …

COVID-19 death rates ‘four times higher’ among those with diabetes and hyperglycemia

APRIL 27, 2020 Mike Watts COVID-19 death rates ‘four times higher’ among those with diabetes and hyperglycemia Hospital teams are being urged to focus on glycemic management among COVID-19 patients with diabetes and hyperglycemia after a research team found mortality rates are higher in people with diabetes. An American team from the Emory University School of Medicine in Georgia say death rates are …

April 25, 2020

Uncontrolled hyperglycemia, diabetes drive longer hospital stay, mortality in COVID-19

APRIL 25, 2020 Regina Schaffer  Uncontrolled hyperglycemia, diabetes drive longer hospital stay, mortality in COVID-19 Adults with diabetes or uncontrolled hyperglycemia hospitalized with COVID-19 experienced a longer length of stay and markedly higher mortality compared with adults without diabetes or uncontrolled hyperglycemia, according to findings published in the Journal of Diabetes Science and Technology. Despite growing evidence that diabetes is …

Risk of Death from COVID-19 Four Times Greater for Those with Diabetes

APRIL 23, 2020 Brian Mastroianni Risk of Death from COVID-19 Four Times Greater for Those with Diabetes People living with diabetes may be at four times greater risk for death from COVID-19 than those who don’t live with the condition. New research has found that people with diabetes and poorly managed hyperglycemia who are hospitalized for COVID-19 have a death …

April 24, 2020

COVID-19 Outcomes Worse With Diabetes, Hyperglycemia

APRIL 24, 2020 COVID-19 Outcomes Worse With Diabetes, Hyperglycemia Length of stay longer, mortality higher for those with diabetes and/or acutely uncontrolled hyperglycemia. Diabetes and/or uncontrolled hyperglycemia occur frequently among hospitalized patients with COVID-19 and are associated with worse outcomes, according to a study accepted for publication in the Journal of Diabetes Science and Technology. Bruce Bode, M.D., from Atlanta …

April 22, 2020

Healthcare Providers Share Results of Computer-Guided Insulin Dosing through Glytec During Diabetes Technology Society’s Virtual Hospital Meeting

Healthcare Providers Share Results of Computer-Guided Insulin Dosing through Glytec During Diabetes Technology Society’s Virtual Hospital Meeting AdventHealth and CHI Franciscan Lead Three-Part Session with Data on Quality and Cost Improvements Achieved Through Electronic Glucose Management WALTHAM, Mass. (April 22, 2020) – Glytec, the only provider of insulin management software across the continuum of care, announced today that AdventHealth and …

April 20, 2020

Study: Pay Attention to In-Hospital Glucose to Save Lives in COVID-19

APRIL 20, 2020 Miriam E. Tucker Study: Pay Attention to In-Hospital Glucose to Save Lives in COVID-19 Diabetes and hyperglycemia among people without prior diabetes are strong predictors of mortality among hospitalized patients with COVID-19, new research suggests. The data suggest that although glycemic control may not be at the forefront of most clinicians’ minds when it comes to COVID-19, …

April 19, 2020

Study: Demanding Better Diabetes Care in Hospitals

APRIL 19, 2020 Mike Hoskins Study: Demanding Better Diabetes Care in Hospitals Poor diabetes care in hospitals has been an issue for some time, but it becomes an even more critical concern as our healthcare workers are being stretched to their breaking point dealing with COVID-19. For many people with diabetes (PWDs), the scariest part about contracting a severe case of the …

April 17, 2020

Study: Patients with COVID-19, Diabetes, Uncontrolled Hyperglycemia Have Significantly Higher Mortality

According to new data from a quality improvement study, patients with diabetes experienced no diabetes-related readmissions, urgent care visits, or emergency department visits within 30 days of hospital discharge when their healthcare providers used Glytec’s eGlycemic Management System to guide insulin regimens prescribed at discharge.

Researchers at Eastern Virginia Medical School conducted the study and presented their findings earlier this month at the 17th Annual Diabetes Technology Meeting in Bethesda, Maryland.

Diabetes patients at four times greater risk of death from COVID-19

APRIL 17, 2020 Diabetes patients at four times greater risk of death from COVID-19 Diabetic and hyperglycemic patients who contract COVID-19 are more than four times as likely to have complications that result in either death or longer hospital stays than their peers without those co-morbidities, according to a new study. An analysis of more than 1,100 COVID-19 patients hospitalized …

COVID-19 Study Shows More than 4 Times In-Hospital Mortality Rate and Increased Length of Stay for Patients with Diabetes and Hyperglycemia

COVID-19 Study Shows More than 4 Times In-Hospital Mortality Rate and Increased Length of Stay for Patients with Diabetes and Hyperglycemia Glytec Research Reveals New Insights Into Important Risk Factors for the Large Population of COVID-19 Patients with Glycemic Control Issues WALTHAM, MASS. (April 17, 2020) – Glytec, the only provider of insulin management software across the continuum of care, …

September 12, 2019

WellStar Health System Expands Use of Glytec’s eGlycemic Management System®

Georgia’s largest health system is heightening the safety and efficacy of insulin therapy across its network of hospitals.

Known nationally for innovative care models, WellStar Health System, in partnership with Glytec, is taking proactive measures to optimize glycemic management for hospitalized patients. The not-for-profit health system is expanding use of Glytec’s patented and FDA-cleared eGlycemic Management System® (eGMS®) beyond its two largest facilities, WellStar Kennestone Hospital and WellStar Atlanta Medical Center, to an additional eight facilities in the Greater Atlanta and surrounding area.

July 30, 2019

Northeast Georgia Medical Center to Implement eGlycemic Management System® from Glytec

The not-for-profit community medical center is partnering with Glytec to facilitate standardization of best practices in diabetes therapy management.

With as many as half of critical care patients either diagnosed with diabetes or at risk of hyperglycemia while hospitalized, Northeast Georgia Medical Center, in partnership with Glytec, is taking advanced measures to optimize glycemic management and ensure the safety and efficacy of insulin therapy. “Our organization is steadfastly committed to clinical excellence in diabetes care and glycemic management,” says Dr. Suhel Patel, Medical Director and Chair, Inpatient Medicine, Northeast Georgia Physicians Group. “By adopting the Glytec suite of technologies and services, our patients will receive insulin therapy that is personalized to their individual needs and carefully designed to support their recovery and transitions of care.”

June 18, 2019

Study Presented at American Diabetes Association 79th Scientific Sessions Observed Substantially Less Hypoglycemia With Use of Glytec’s Technology

Results of a study by Drs. Guillermo Umpierrez and Jordan Messler observed markedly lower rates of hypoglycemia and hyperglycemia among critical care patients managed with Glytec’s eGlycemic Management System® versus usual care.

Delivering the highest quality care in accordance with best practice is a fundamental tenet of diabetes and glycemic management at Grady Hospital of Atlanta, Georgia, which is why in 2016, the academic medical center chose to standardize its approach and elevate both safety and efficacy by implementing Glytec’s eGlycemic Management System® (eGMS®) in its intensive care and step-down units. A retrospective analysis conducted by Drs. Guillermo Umpierrez and Jordan Messler, and presented at the American Diabetes Association 79th Scientific Sessions, observed that outcomes of patients managed with eGMS® were consistently superior to those managed with a standard protocol. Outcomes measured over a two-year period (December 2016 to December 2018) included incidence of hypoglycemia, incidence of hyperglycemia, target glucose attainment, and reduction in admission-to-discharge blood glucose.

November 13, 2018

Study by Riverside Medical Center Shows Reductions in Length of Stay and Hypoglycemia with Glytec’s Insulin Optimization Solution

Presented at the 18th Annual Diabetes Technology Meeting, the study found that patients treated using Glytec’s solution had 73.2% less hypoglycemia and no bounce backs once transferred from a CCU to a general ward.

With a shifting reimbursement landscape and acuity on the rise for hospitalized patients, the need to minimize length of stay and increase throughput in critical care units is a priority for health systems nationwide. A study conducted by Riverside Medical Center of Kankakee, Illinois, the flagship facility of Riverside Healthcare and the area’s only Magnet® recognized institution, found that by using Glytec’s eGlycemic Management System® (eGMS®), patients admitted to critical care units were transferred to general wards .25 days sooner and there were no “bounce backs,” or returns from general wards to critical care units. The study, presented at the 18th Annual Diabetes Technology Meeting, also found that severe hypoglycemia among patients in critical care units was 73.2% lower when using eGMS®.

June 7, 2017

Case Studies Presented at Diabetes Technology Society Conference Highlight Millions in Hospital Cost Savings with Improved Glucose Control

One study presented at the International Hospital Diabetes Meeting observed first-year cost savings of nearly $7.5 million stemming from adoption of best practice for insulin therapy.

A series of studies and presentations included in the 6th International Hospital Diabetes Meeting highlighted the high cost of poor glucose management, and in particular, severe hypoglycemia (< 40 mg/dL) in the acute care setting. With thirty to forty percent of ALL hospitalized patients requiring insulin therapy, not just those with diabetes, the common problem of insulin mismanagement has significant impact on care quality, patient safety and patient experience, as well as cost and value.

April 26, 2017

Research Study from Emory University Observes $3,654 Per Patient Cost Savings for CABG Surgery

Drs. Umpierrez and Cardona publish economic and clinical results of the GLUCO-CABG trial, leveraging Glytec’s Glucommander™ for personalized insulin dosing.

A study from Emory University published in the April 2017 issue of Journal of Diabetes and Its Complications (Cardona, et al. 2017) observes a near-20% reduction in perioperative complications, a 1.2-day reduction in ICU stay and a $3,654 reduction in per-patient hospitalization costs for coronary artery bypass graft (CABG) surgery. The reported outcomes, which included no severe hypoglycemia less than 40 mg/dL, were derived from an intensive glycemic control protocol supported by Glytec’s Glucommander™ for personalized insulin dosing.